Clarus Ventures β Full Portfolio
7 tracked investments Β· listed companies and verified rows first
BiotechBurlingame, US
Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)Timothy Smith(Executive Officer)
BoardAlfred Scheidegger(Director)inPeter Thompson(Director)Carol Gallagher(Director)
Co-investorsAstellas Venture Management LLCNew Enterprise Associates (NEA)Nextech Invest5AM VenturesOrbiMedOsage University Partners+1 more
Developed a next-generation iron chelator for iron overload in transfusion-dependent anemia; acquired by Shire in 2012.
BiotechSan Carlos, US
Hugh Y. Rienhoff, Jr., M.D.(Executive Officer, Director)in
BoardMarten Steen(Director)Dennis Henner, Ph.D.(Director)Bryant E. Fong(Director)
Co-investorsMC Healthcare Ventures
HealthtechMt Olive, US
Louis Altieri(Executive Officer)Larry Heaton(Executive Officer)in
BoardSteven C. Adler(Director)David Jenkins(Director)Kurt Wheeler(Director)Donald P. Carson(Director)
Co-investorsClarus
A pharmaceutical company that develops medicines and vaccines, with research pipelines and clinical trials aimed at new treatments.
BiotechHealthtech
Co-investorsHighlight CapitalAmgen VenturesFrazier Healthcare Partners
HealthtechSan Carlos, US
Hugh Y. Rienhoff(Executive Officer, Director)inLaura G. Eichorn(Executive Officer)in
BoardPatrick Heron(Director)inDennis Henner(Director)Alan Sachs(Director)
Co-investorsAmgen VenturesFrazier Healthcare PartnersFrazier Life Sciences
Lumos Pharma is a clinical-stage biopharmaceutical company developing therapies for rare diseases, with a lead candidate targeting Pediatric Growth Hormone Deficiency.
BiotechHealthtechAustin, US
Richard John Hawkins(Executive Officer, Director)John C. McKew(President and Chief Scientific Officer)inPisit "Duke" Pitukcheewanont(Chief Medical Officer)inLori Lawley(Chief Financial Officer)inBrad Powers(Chief Compliance Officer and General Counsel)inCampbell Murray(Executive Chairman)in
Co-investorsNew Enterprise Associates (NEA)Deerfield Management CompanySante Health VenturesSante VenturesWellcome Trust
VBI Vaccines is a biopharmaceutical company developing vaccine candidates using virus-like particle (VLP) platforms, including proprietary enveloped VLP and mRNA-launched eVLP technologies.
BiotechHealthtechCambridge, US
Marc Kirchmeier(Vice President, Formulation Development)Egidio Nascimento(Chief Financial Officer)inDavid Anderson(Senior Vice President, Research)inJeff Baxter(President and Chief Executive Officer)inAdam T. Buckley(Vice President, Business Development)inMurray G. Smith(Executive Officer)
Co-investors5AM VenturesARCH Venture PartnersK2 HealthVentures
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.